Diurnal's 'Efmody' treatment gets thumbs-up for NHS Wales
7th Oct 2022 11:31
(Sharecast News) - Specialty pharmaceutical company Diurnal Group announced on Friday that the All-Wales Medicines Strategy Group (AWMSG) has recommended its 'Efmody' hydrocortisone modified-release hard capsules as an option for restricted use to treat adolescents and adults with congenital adrenal hyperplasia (CAH) within NHS Wales.
Read moreDiurnal to be taken over by Neurocrine Biosciences for £48.3m, shares surge
30th Aug 2022 14:55
(Sharecast News) - Diurnal shares surged on Tuesday after it agreed to be taken over by US biotech firm Neurocrine Biosciences for £48.3m.
Read moreDirector dealings: K3 director linked to purchase, Diurnal exec sells shares into ISA
9th May 2022 14:01
(Sharecast News) - Software company K3 Business Technology was at the top of the list of buys on Monday, after Kestrel Partners spent more than £40k on its shares.
Read moreDiurnal inks distribution agreement with Vector Pharma
30th Mar 2022 08:55
(Sharecast News) - Pharmaceutical company Diurnal has inked a distribution agreement with Vector Pharma for its Alkindi asset across the Middle East and North Africa.
Read moreDiurnal agrees special protocol with FDA for Chronocort study
12th Jul 2021 10:10
(Sharecast News) - Specialty pharmaceutical company Diurnal announced on Monday that the US Food and Drug Administration (FDA) has agreed a special protocol assessment (SPA) for 'Chronocort', or modified-release hydrocortisone, for the design, endpoints and statistical analysis approach of a pivotal study of the product, for the treatment for congenital adrenal hyperplasia (CAH).
Read moreDiurnal gets UK approval for 'Efmody' treatment
2nd Jul 2021 10:02
(Sharecast News) - Speciality pharmaceutical company Diurnal Group announced on Friday that the UK Medicines and Healthcare products Regulatory Agency (MHRA) has granted a marketing authorisation for 'Efmody', or hydrocortisone modified-release hard capsules, as treatment for adult and adolescent patients with the rare congenital adrenal hyperplasia (CAH) condition.
Read moreDiurnal granted European patent for Alkindi
23rd Apr 2021 10:31
(Sharecast News) - Hormonal disease-focussed speciality pharmaceutical company Diurnal Group announced the grant of a patent for 'Alkindi', or hydrocortisone granules in capsules for opening, by the European Patent Office on Friday.
Read moreAlkindi sales drive revenue higher for Diurnal
23rd Feb 2021 16:23
(Sharecast News) - Speciality pharmaceuticals company Diurnal reported 6% growth in first-half total revenue in its interim results on Tuesday, to £1.21m.
Read moreDiurnal gets European patent for 'Alkindi'
20th Nov 2020 12:04
(Sharecast News) - Speciality pharmaceutical company Diurnal Group announced the grant of a patent for 'Alkindi', or hydrocortisone granules in capsules for opening, by the European Patent Office on Friday.
Read moreDiurnal up as its partner advances Swiss authorisation for 'Alkindi'
21st Oct 2020 15:40
(Sharecast News) - Speciality pharmaceuticals company Diurnal Group announced on Wednesday that its marketing and distribution partner in Switzerland, EffRx Pharmaceuticals, has submitted a market authorisation application to Swissmedic for the registration of 'Alkindi', or hydrocortisone granules in capsules for opening, in the country.
Read moreDiurnal raising up to £10m in placing and open offer
9th Oct 2020 16:13
(Sharecast News) - Speciality pharmaceuticals company Diurnal Group announced a proposed conditional placing with institutional investors to raise up to £8m before expenses on Friday, at a price of 60p per share, and an open offer to raise up to a further £2m.
Read moreDiurnal signs two new distribution agreements in Europe
3rd Sep 2020 11:35
(Sharecast News) - Speciality pharmaceutical company Diurnal Group announced two further European market and distribution agreements for its products 'Alkindi', or hydrocortisone granules in capsules for opening, and 'Chronocort', or modified release hydrocortisone, on Thursday.
Read moreDiurnal raises at least ?7m through conditional placing
6th Mar 2020 10:07
(Sharecast News) - Speciality pharmaceutical company Diurnal Group announced a conditional placing with institutional investors on Friday, to raise at least ?7m before expenses, at a price of 32p per new share.
Read moreDiurnal clears FDA hurdle for 'Alkindi Sprinkle'
13th Feb 2020 09:47
(Sharecast News) - Speciality pharmaceutical company Diurnal Group announced on Thursday that its new drug application (NDA) for 'Alkindi', or hydrocortisone granules in capsules for opening and to be known in the US as 'Alkindi Sprinkle', has been accepted for review by the US Food and Drug Administration (FDA).
Read moreDiurnal narrows loss as it progresses drugs to market
11th Feb 2020 13:45
(Sharecast News) - Speciality pharmaceutical company Diurnal Group narrowed its first-half loss by 53% to ?4.6m, it announced on Tuesday, which it said reflected improved revenues and a reduction in clinical development expenses for the period.
Read more